Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 4/20 | 0.40 |
| ▸ | MCHR1 | Q99705 | 10/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | MMP14 | P50281 | 1/20 | 0.37 |
| ▸ | BMP1 | P13497 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5564847 | 0.90 | RXFP1 (0.44) | NPC1RAB9ASMN1; SMN2L3MBTL1CNR2 | |
| SCHEMBL5564958 | 0.88 | RXFP1 (0.45) | NPC1RAB9ASMN1; SMN2L3MBTL1CNR2 | |
| SCHEMBL5564059 | 0.87 | NPC1 (0.47) | NPC1RAB9ASMN1; SMN2L3MBTL1CNR2 | |
| SCHEMBL5565724 | 0.85 | NPC1 (0.44) | NPC1RAB9ASMN1; SMN2L3MBTL1CNR2 | |
| SCHEMBL5563555 | 0.83 | RAB9A (0.44) | NPC1RAB9ASMN1; SMN2L3MBTL1CNR2 | |
| SCHEMBL5566157 | 0.83 | RAB9A (0.41) | NPC1RAB9ASMN1; SMN2L3MBTL1CNR2 | |
| SCHEMBL5563050 | 0.82 | RXFP1 (0.45) | NPC1RAB9ASMN1; SMN2L3MBTL1ALDH1A1 | |
| SCHEMBL5564192 | 0.81 | RXFP1 (0.46) | NPC1SMN1; SMN2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL5559654 | 0.80 | RXFP1 (0.54) | NPC1CNR2ALDH1A1KDM4E | |
| SCHEMBL5564303 | 0.80 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2L3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7208491-B2 | N-monoacylated o-phenylenediamines | HOFFMANN-LA ROCHE INC. (US) | 2007-04-24 | — | — | US | disclosed |
| EP-1594857-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI-CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069133-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI -CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HOFFMANN-LA ROCHE INC. | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HDAC1, HDAC11, HDAC7 | NPC1 1590/4885RAB9A 3181/4885SMN1; SMN2 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.